{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T09:53:42Z","timestamp":1770976422478,"version":"3.50.1"},"reference-count":64,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2014,1,20]],"date-time":"2014-01-20T00:00:00Z","timestamp":1390176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2014,7]]},"abstract":"<jats:p>Recent advances in therapies for the treatment of type 2 diabetes mellitus (<jats:styled-content style=\"fixed-case\">T2DM<\/jats:styled-content>) have led to the development of glucagon\u2010like peptide\u20101 receptor agonists (<jats:styled-content style=\"fixed-case\">GLP<\/jats:styled-content>\u20101 <jats:styled-content style=\"fixed-case\">RAs<\/jats:styled-content>), which, unlike insulin and sulphonylurea, are effective, with a low risk of hypoglycaemia. Lixisenatide is recommended as a once\u2010daily <jats:styled-content style=\"fixed-case\">GLP<\/jats:styled-content>\u20101 <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> for the treatment of <jats:styled-content style=\"fixed-case\">T2DM<\/jats:styled-content>. In persons with <jats:styled-content style=\"fixed-case\">T2DM<\/jats:styled-content>, lixisenatide 20\u2009\u00b5g once\u2010daily given by bolus subcutaneous injection improves insulin secretion and suppresses glucagon secretion in a glucose\u2010dependent manner. Compared with the longer\u2010acting <jats:styled-content style=\"fixed-case\">GLP<\/jats:styled-content>\u20101 <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> liraglutide, lixisenatide achieved a significantly greater reduction in postprandial plasma glucose (<jats:styled-content style=\"fixed-case\">PPG<\/jats:styled-content>) during a standardized test breakfast in persons with <jats:styled-content style=\"fixed-case\">T2DM<\/jats:styled-content> otherwise insufficiently controlled on metformin alone. This is primarily due to the greater inhibition of gastric motility by lixisenatide compared with liraglutide. The efficacy and safety of lixisenatide was evaluated across a spectrum of <jats:styled-content style=\"fixed-case\">T2DM<\/jats:styled-content> in a series of phase <jats:styled-content style=\"fixed-case\">III<\/jats:styled-content>, randomized, placebo\u2010controlled trials known as the <jats:styled-content style=\"fixed-case\">GetGoal<\/jats:styled-content> programme. Lixisenatide monotherapy or as add\u2010on to oral antidiabetic agents or basal insulin achieved significant reductions in glycated haemoglobin, <jats:styled-content style=\"fixed-case\">PPG<\/jats:styled-content> and fasting plasma glucose, with either weight loss or no weight gain. The most frequent adverse events were gastrointestinal and transient in nature. Lixisenatide provides an easy, once\u2010daily, single\u2010dose, add\u2010on treatment to oral antidiabetic agents or basal insulin for the management of <jats:styled-content style=\"fixed-case\">T2DM<\/jats:styled-content>, with little or no increased risk of hypoglycaemia and a potential beneficial effect on body weight.<\/jats:p>","DOI":"10.1111\/dom.12253","type":"journal-article","created":{"date-parts":[[2013,12,24]],"date-time":"2013-12-24T08:28:42Z","timestamp":1387873722000},"page":"588-601","source":"Crossref","is-referenced-by-count":34,"title":["Lixisenatide, a novel <scp>GLP<\/scp>\u20101 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus"],"prefix":"10.1111","volume":"16","author":[{"given":"G. B.","family":"Bolli","sequence":"first","affiliation":[{"name":"Department of Medicine University of Perugia, Hospital S.M. della Misericordia Perugia Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. R.","family":"Owens","sequence":"additional","affiliation":[{"name":"Diabetes Research Group, Institute of Life Sciences, College of Medicine Swansea University Swansea UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,1,20]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0413"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2008.00881.x"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2006.01.004"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.85.10.3575"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021053"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116186"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1210\/endo.134.5.8156917"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2012.140"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01560.x"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0801627"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00545.2003"},{"key":"e_1_2_9_13_1","doi-asserted-by":"crossref","first-page":"902","DOI":"10.2337\/diab.38.7.902","article-title":"Glucagonostatic and insulinotropic action of glucagonlike peptide I\u2010(7\u201336)\u2010amide","volume":"38","author":"Komatsu R","year":"1989","journal-title":"Diabetes"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00401145"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.81.1.327"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.2337\/db09-1414"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/68.3.525"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.1202"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.3.8355"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1262-3636(08)73398-6"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00034.2006"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.2165\/00126839-200708030-00002"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2008.08.002"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61206-4"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60406-0"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-2081"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/1479164112441526"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.5414\/CP201462"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009339189"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-1393"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60659-0"},{"issue":"1","key":"e_1_2_9_32_1","first-page":"S1","article-title":"Introduction: the American Diabetes Association's (ADA) evidence\u2010based practice guidelines, standards, and related recommendations and documents for diabetes care","volume":"35","author":"American Diabetes Association","year":"2012","journal-title":"Diabetes Care"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)36565-2"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543780902766802"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-001-0719-z"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.8.1398"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2009.03.008"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.2337\/db10-0474"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01557.x"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp050459"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2454"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2462"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01618.x"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-2191"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-154-2-201101180-00300"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP.13.5.444"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1042426"},{"key":"e_1_2_9_48_1","unstructured":"LiuYH RuusP.Pharmacokinetics and safety of the GLP\u20101 agonist AVE0010 in patients with renal impairment. Abstract presented at the 69th Scientific Session of the American Diabetes Association 5\u20139 June 2009 New Orleans USA. Diabetes2009;59(Suppl. 1):A149\u2013A150."},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1935"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2006"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12328"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2709"},{"issue":"1","key":"e_1_2_9_53_1","first-page":"A785","article-title":"Efficacy and safety of lixisenatide once daily versus placebo in patients with T2DM insufficiently controlled on sulfonylurea\u00b1metformin (GetGoal\u2010S) [Abstract]","volume":"54","author":"Ratner R","year":"2011","journal-title":"Diabetologia"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.regpep.2013.04.001"},{"key":"e_1_2_9_55_1","first-page":"A212","article-title":"Augmentation of 1st\u2010phase insulin release with lixisenatide in non\u2010diabetic subjects (Abstract 1149\u2010P)","volume":"61","author":"Becker R","year":"2012","journal-title":"Diabetes"},{"key":"e_1_2_9_56_1","first-page":"A212","article-title":"Restitution of glucose disposition with lixisenatide in T2DM subjects (Abstract 1081\u2010P)","volume":"61","author":"Becker R","year":"2012","journal-title":"Diabetes"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2010.03020.x"},{"key":"e_1_2_9_58_1","unstructured":"WernerU Kuhlmann\u2010GottkeJ RuettenH Sch\u00e4ferH\u2010L HerlingAW. Comparison of the once\u2010daily GLP\u20101R agonists lixisenatide and liraglutide on prandial carbohydrate utilization in animal models. Poster presented at the International Diabetes Federation's 21st World Diabetes Congress 5\u20138 December2001 Dubai United Arab Emirates 2001. Poster D\u20100737."},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12076"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-2593"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12121"},{"key":"e_1_2_9_62_1","first-page":"A212","article-title":"Efficacy and safety of lixisenatide in elderly (\u226565 yr) and very elderly (\u226575 yr) patients with type 2 diabetes: an analysis from the GetGoal Phase 3 program (Abstract 972\u2010P)","volume":"61","author":"Raccah D","year":"2012","journal-title":"Diabetes"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-9025"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00265086"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-013-0009-4"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12253","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12253","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T16:17:13Z","timestamp":1760372233000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,20]]},"references-count":64,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["10.1111\/dom.12253"],"URL":"https:\/\/doi.org\/10.1111\/dom.12253","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,20]]}}}